Brilliant Blue G

Prescription

Ticari adlar: TISSUEBLUE

Farmasötik Form

Other

Uygulama Yolu

INTRAOCULAR

Üretici

D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.

About This Medication

TissueBlue 0.025% - Description section TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a sterile solution of BBG (a dye) for intraocular ophthalmic use. Each mL of TissueBlue 0.025% contains BBG 0.25 mg, polyethylene glycol and buffered sodium chloride solution (sodium chloride, dibasic sodium phosphate, monobasic sodium phospage, water for injection). Phosphoric acid and/or sodium hydroxide may also be used for pH adjustment. The pH range of TissueBlue 0.025% Solution is between 7.3 and 7.6. The drug substance BBG has the chemical name Brilliant Blue G, a molecular weight of 854.02 and has the following chemical structure: Molecular formula: C 47 H 48 N 3 NaO 7 S 2 BBG.jpg

Etken Maddeler

Bileşen	Güç
Brilliant Blue G	-

Endikasyonlar ve Kullanım

TissueBlue 0.025% - Indications & Usage Section TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM). TissueBlue 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM).

Nasıl çalışır

TissueBlue 0.025% - Mechanism of action section Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.

Dozaj ve Uygulama

TissueBlue 0.025% - Dosage & Administration Section TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity. Inject TissueBlue 0.025% directly in a Balanced Salt Solution (BSS)-filled vitreous cavity. Excess TissueBlue should be removed from the vitreous cavity.

Side Effects Overview

TissueBlue 0.025% - Adverse Reactions section Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure. These complications include retinal (retinal break, tear, hemorrhage, and detachment) and cataracts. Adverse reactions that have been reported in procedures that included the use of TissueBlue 0.025% have often been associated with the surgical procedure. The complications include retinal (retinal break, tear, hemorrhage, and detachment and cataracts. To report SUSPECTED ADVERSE REACTIONS, contact Dutch Ophthalmic, USA at 1-800-75-DUTCH or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Uyarılar ve Önlemler

TissueBlue 0.025% - Warnings and Precautions section Excessive Staining Excess TissueBlue 0.025% should be removed from the eye immediately after staining. Use of the Syringe Make sure the plunger moves smoothly before injecting the solution. Do not use the product if the plunger does not move smoothly to prime the cannula. Excessive staining: Excess TissueBlue 0.025% should be removed from the eye immediately after staining. Use of the syringe: Make sure the plunger moves smoothly before injecting the solution.

Kontrendikasyonlar

TissueBlue 0.025% - Contraindications section None None

Frequently Asked Questions

TissueBlue 0.025% - Indications & Usage Section TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM). TissueBlue 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM).

TissueBlue 0.025% - Dosage & Administration Section TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity. Inject TissueBlue 0.025% directly in a Balanced Salt Solution (BSS)-filled vitreous cavity. Excess TissueBlue should …

TissueBlue 0.025% - Warnings and Precautions section Excessive Staining Excess TissueBlue 0.025% should be removed from the eye immediately after staining. Use of the Syringe Make sure the plunger moves smoothly before injecting the solution. Do not use the product if the plunger does not move smoothly to prime the cannula. Excessive staining: Excess TissueBlue 0.025% should be removed from the eye immediately after staining. Use of the syringe: Make sure the plunger moves smoothly before injecting the solution.

TissueBlue 0.025% - Contraindications section None None

Brilliant Blue G is a prescription medication. You will need a valid prescription from a licensed healthcare provider.

Similar Other Products

Avacincaptad Pegol

Ranibizumab-Nuna

Elagolix And Estradiol And …

Daytime - Acetaminophen, Dextromethrophan …

Fucus Vesiculosus

Tarlatamab-Dlle

Browse all Other products →

References & Data Sources

• DailyMed — Brilliant Blue G drug label (National Library of Medicine)
• openFDA — Brilliant Blue G label data (U.S. Food & Drug Administration)
• NDC Directory — Brilliant Blue G (FDA National Drug Code)

Tıbbi Sorumluluk Reddi

Bu sayfadaki bilgiler yalnızca eğitim amaçlıdır ve profesyonel tıbbi tavsiye, teşhis veya tedavinin yerine geçmek amacıyla kullanılmamalıdır.

Bir tıbbi durum veya ilaçla ilgili sorularınız için her zaman doktorunuzun veya nitelikli başka bir sağlık uzmanının tavsiyesine başvurun.

Veri kaynakları: DailyMed (NLM), openFDA, MFDS